Development of oral oncolytic nonadherence estimator (ORACLE): A pretreatment nonadherence risk assessment for oral oncolytics

Author:

Signorelli Jessie1ORCID,Tran Thuy2,Sirek Marie E3,Díaz-Rohena Yarelis4,Taraba Jodi L5,Muluneh Benyam67ORCID,Basu Nayanika8,Lilly Jennifer9,Darling Julianne10

Affiliation:

1. Pharmacy, Massachusetts General Hospital, Boston, MA, USA

2. Specialty Pharmacy Services, Atrium Health, Charlotte, NC, USA

3. Department of pharmacy, Billings Clinic, MT, USA

4. NCODA University, National Community Oncology Dispensing Association, Cazenovia, NY, USA

5. Department of Pharmacy, Mayo Clinic, Rochester, MN, USA

6. Division of Pharmacotherapy and Experimental Therapeutics, University of Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA

7. Cancer Prevention and Control Program, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA

8. Department of Pharmacy, University of Virginia Breast Care Center, Charlottesville VA, USA

9. Department of Pharmacy, Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN, USA

10. NCODA University, National Community Oncology Dispensing Association, Birmingham, AL, USA

Abstract

Introduction To date, there is no adherence estimator to identify risk of nonadherence prior to initiating oral oncolytics. Methods A workgroup was assembled through the National Community Oncology Dispensing Association and tasked with creating a tool to meet this need. Tool constructs were defined after a review of the literature identifying top barriers to adherence. A second literature search was conducted to identify questions targeting specific barriers from validated adherence questionnaires. Once a finalized draft was complete, the risk assessment tool was built into an electronic survey where a risk category can be automatically calculated for the patient. Results The six most impactful factors affecting compliance to oral oncolytics were identified as patient's confidence, health literacy, perception of treatment, quality of life, social support, and complexity of chemotherapy regimen. A six-item questionnaire was created with five patient-directed questions and one clinician-directed question. Examples and descriptions were provided for clinicians to consider when categorizing complexity of a regimen. The tool was designed for responses to each question to be indexed into categories through a 10-point system. Results will be stratified into low, moderate, or high risk for nonadherence. Conclusion The creation of a tool to predict nonadherence prior to starting therapy is an unmet need for patients initiating oral oncolytics. The aim of this tool is to meet those needs and better guide clinicians to provide patients with strategies to better manage nonadherence. Next steps include tool validation and piloting in clinical practice.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Oncology

Reference43 articles.

1. Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of Life

2. Patient Medication Adherence: Measures in Daily Practice

3. Adherence to oral chemotherapy: Evidence from a randomised clinical trial

4. National Community Oncology Dispensing Association. Oral Oncolytic Non-Adherence in Medically Integrated Dispensing Pharmacies, https://www.ncoda.org/oral-oncolytic-non-adherence-in-medically-integrated-dispensing-pharmacies/ (2022, accessed 10 February 2023).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3